Skip to main content
. Author manuscript; available in PMC: 2019 Mar 7.
Published in final edited form as: Knee. 2018 Mar 7;25(2):296–305. doi: 10.1016/j.knee.2018.01.009

Table 4.

Influence of Time Frames and Covariates on ARGS collected at the Six-Month Follow-Up Exam and Days Between Injury and Surgery

Covariate R2 (Unstandardized β) Between Covariate and ARGS ΔR2 (Unstandardized β) Between Injury and Surgery and ARGS after accounting for the covariate
Days Between Injury and Six-Month Follow-up 0.069 (−0.001) 0.008 (0.0003)
Days Between ACLR and Six-Month Follow-up 0.073 (−0.001) 0.008 (−0.0003)
Body Mass Index 0.016 (0.002) 0.005 (−0.0002)
Sex 0.003 (−0.004) 0.002 (−0.0001)
Age 0.133 (−0.004) 0.006 (0.0003)
History of previous ACLR 0.217 (0.048) * 0.002 (−0.0002)
Concomitant Meniscal Injury 0.005 (−0.007) 0.002 (−0.0001)
Concomitant Chondral Injury 0.139 (0.035) 0.007 (0.0003)
KOOS Symptoms at Initial Presentation 0.002 (−0.0001) 0.002 (−0.0001)
KOOS Pain at Initial Presentation 0.147 (−0.001) 0.015 (−0.0004)
KOOS Daily Living at Initial Presentation 0.004 (0.0001) 0.005 (−0.0002)
KOOS Sports at Initial Presentation 0.098 (−0.0005) 0.019 (−0.0005)
KOOS Quality of Life at Initial Presentation 0.037 (0.0004) 0.004 (0.0002)
Tegner Activity Scale at Six-Month Follow-Up 0.040 (−0.004) 0.00002 (−0.00001)

ACLR – Anterior Cruciate Ligament Reconstruction, KOOS – Knee Osteoarthritis and Outcome Score, C2C – Type-II Collagen Cleavage Product, CPII – C-Propeptide of Type-II Collagen Procollagen, ARGS – Alanin-Arginine-Glycine-Serine, IL-6 – Interleukin-6, MMP-3 – Matrix Metalloproteinase-3

*

Significant F Change at p ≤ 0.05